Making personalized medicine practical

By Starr McCaffery

In August, the U.S. Food and Drug Administration (FDA) announced a labeling change for the widely used blood-thinning drug warfarin (Coumadin®), designed to increase patient safety. The change is a recommendation for prescribing physicians to use genetic test results to optimize warfarin dosage.

Although genetic tests are not required by the new FDA labeling, the change highlights the opportunity for orthopaedic surgeons, as well as for other healthcare providers who prescribe warfarin, to lower patients’ risk of bleeding complications.

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!